Journals / Anadolu Kardiyoloji Dergisi / 2009 / Cilt: 9 - Sayı: 3

Management of diabetes in cardiac diseases

Kalp hastalıklarında diyabet yönetimi

Pages
238–247
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The management of patient with type 2 DM is not only glucocentric but focuses on multiple risk factor intervention.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Type 2 diabetes mellitus (DM) is a common disease affecting people in the world and its incidence is increasing rapidly.
📊
Key Findings & Data:Cardiovascular disease (CVD) is the most important cause of mortality and morbidity among patients with type 2 DM.
💡
Conclusion & Impact:The management of patient with type 2 DM is not only glucocentric but focuses on multiple risk factor intervention.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Type 2 diabetes mellitus (DM) is a common disease affecting people in the world and its incidence is increasing rapidly. Cardiovascular disease (CVD) is the most important cause of mortality and morbidity among patients with type 2 DM. Patients with diabetes have a poorer prognosis than patients without diabetes. It is well known that other cardiovascular risk factors such as hyperlipidemia, hypertension and obesity that usually accompany to diabetes mellitus or impaired glucose tolerance as a metabolic syndrome component or not, can contribute to accelerated atherosclerosis and increased risk of cardiovascular event in diabetes mellitus. The management of patient with type 2 DM is not only glucocentric but focuses on multiple risk factor intervention.

Özet

Tip 2 diyabetes mellitus (DM) dünyada en sık görülen hastalıklardan birisidir ve sıklığı giderek artmaktadır. Kardiyovasküler hastalıklar, tip 2 diyabetik hastalardaki mortalite ve morbiditenin en önemli nedenidir. Kardiyovasküler mortalite diyabetik olmayanlara göre diyabetli hastalarda belirgin olarak artmıştır. Diyabet ve bozulmuş glukoz toleransına genelde metabolik sendrom komponenti olarak veya olmadan sıklıkla eşlik eden hiperlipidemi, hipertansiyon ve obezite gibi diğer kardiyovasküler risk faktörlerinin de diyabetteki hızlanmış ateroskleroz ve artmış kardiyovasküler risk artışına katkısı olduğu bilinmektedir. Bu nedenle diyabet tedavisinde sadece kan şekeri regülasyonu ile yetinmemek aynı zamanda eşlik eden sorunlara da odaklanmak gerekmektedir.

🔖

Cite This Article

AYDIN, Y., BERKER, D., IŞIK, S., DELİBAŞI, T., GÜLER, S. (2022). Management of diabetes in cardiac diseases. Anadolu Kardiyoloji Dergisi, Cilt: 9 - Sayı: 3, 238–247. https://ajindex.com/articles/436846

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995- 2025. Diabetes Care 1998; 21: 1414- 31
  2. Satman I, Yılmaz T, Şengül A, Salman S, Salman F, Uygur S, et al. Population-based study of diabetes and risk characteristics in Turkey: results of the Turkish diabetes epidemiology study (TURDEP). Diabetes Care 2002; 25: 1551-6
  3. Johnstone MT, Nesto R. Diabetes mellitus and heart disease. In: Pickup JC, Williams G, editors. Joslin's Diabetes Mellitus. 14th ed. Philadelphia: Lippincott Williams and Wilkins; 2005. p. 975- 98
  4. Öngen Z. Ateroskleroz patogenezi. Erol Ç, editör. Klinik Kardiyoloji. Birinci baskı. Ankara: Nobel Yayınevi; 2004. s.1-20
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
  6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
  7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12
  8. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-7
  9. Haffner SM, D'Agostino R Jr, Mykkänen L, Tracy R, Howard B, Rewers M, et al. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562-8
  10. McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD, et al. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J 2000; 21: 1750-8
  11. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995; 26: 57-